Konopka L
Klinika Chorób Wewnetrznych, Instytut Hematologii i Transfuzjologii w Warszawie.
Acta Haematol Pol. 1994;25(2 Suppl 1):163-75.
The results of clinical trials suggest that human hematopoietic factors are very usefull in overcoming neutropenia. Particularly, the great clinical benefit after G-CSF, GM-CSF therapy is observed in different types of neutropenia (cyclic, chronic neutropenia) aplastic anaemia, and neutropenias in infection diseases. At present, in acquired immunodeficiency syndrome, GM-CSF and other CSFs are envisioned in a primarily adjunctive role, supporting blood counts during period of myelosuppressive drug therapy.
临床试验结果表明，人类造血因子在克服中性粒细胞减少方面非常有用。特别是，在不同类型的中性粒细胞减少症（周期性、慢性中性粒细胞减少症）、再生障碍性贫血以及感染性疾病中的中性粒细胞减少症患者中，观察到粒细胞集落刺激因子（G-CSF）、粒细胞-巨噬细胞集落刺激因子（GM-CSF）治疗后具有显著的临床益处。目前，在获得性免疫缺陷综合征中，GM-CSF和其他集落刺激因子（CSF）主要设想发挥辅助作用，在骨髓抑制性药物治疗期间维持血细胞计数。
